Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) PT at $24.67

CeriBell, Inc. (NASDAQ:CBLL) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $24.6667.

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group raised their price target on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th.

Insider Transactions at CeriBell

In related news, CTO Raymond Woo sold 11,112 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $21.18, for a total value of $235,352.16. Following the transaction, the chief technology officer owned 167,317 shares of the company’s stock, valued at $3,543,774.06. This trade represents a 6.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Josef Parvizi sold 25,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $22.94, for a total transaction of $573,500.00. Following the completion of the sale, the director directly owned 747,652 shares of the company’s stock, valued at approximately $17,151,136.88. This trade represents a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 203,627 shares of company stock valued at $4,156,660. Company insiders own 20.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CBLL. Vanguard Group Inc. increased its holdings in CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the period. Yu Fan lifted its holdings in shares of CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after buying an additional 130,964 shares during the period. Bank of New York Mellon Corp grew its position in shares of CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares in the last quarter. KCM Capital Inc purchased a new position in shares of CeriBell during the fourth quarter valued at $21,930,000. Finally, Novo Holdings A S increased its stake in shares of CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after buying an additional 20,000 shares during the period.

CeriBell Price Performance

CBLL stock opened at $17.77 on Friday. The stock has a market cap of $668.86 million, a PE ratio of -12.09 and a beta of 1.13. CeriBell has a 12 month low of $10.01 and a 12 month high of $24.33. The company has a 50-day moving average price of $19.69 and a 200 day moving average price of $17.26. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The company had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million. Equities research analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.